Bruce I Walker

US Patent:

6852508, Feb 8, 2005

Filed:

Oct 20, 1998

Appl. No.:

09/175713

Inventors:

Stephen H. Herrmann - Wellesley MA, US
Zhijian Lu - Bedford MA, US
John M. McCoy - Reading MA, US
Stephen L. Swanberg - Boston MA, US
Bruce Walker - Charlestown MA, US
Otto Yang - Charlestown MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA
The General Hospital Corporation - Boston MA

International Classification:

C12P021/06
C07H021/04
C07H014/00
A61K038/00

US Classification:

435 691, 536 235, 530324, 514 2

Abstract:

This invention provides polynucleotides comprising sequences encoding amino-terminal-modified chemokines, the encoded amino-terminal-modified chemokines, and uses thereof.

US Patent:

6974574, Dec 13, 2005

Filed:

Aug 16, 2002

Appl. No.:

10/222463

Inventors:

Bruce D. Walker - Milton MA, US
Marcus Altfeld - Arlington MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K039/00

US Classification:

4241921, 4241851, 4241881, 42419611, 4242021, 4242081, 530350, 530328, 530826

Abstract:

The invention features an immunogenic composition containing a frequently-recognized epitope of an HIV-1 accessory protein such as Vpr and methods of inducing an immune response using such an epitope. The epitope peptide contains the amino acid sequence ALIRILQQL of a functionally active domain or a structural domain of the accessory protein.

US Patent:

7201904, Apr 10, 2007

Filed:

May 16, 2003

Appl. No.:

10/440390

Inventors:

Georg Lauer - Cambridge MA, US
Kei Ouchi - Cambridge MA, US
Bruce D. Walker - Milton MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 39/00
A61K 39/12
A61K 39/29
C07K 4/02
C07K 7/00

US Classification:

4241891, 4241841, 4241861, 4242281, 530300, 514 2

Abstract:

The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.

US Patent:

7510828, Mar 31, 2009

Filed:

Jul 15, 2004

Appl. No.:

10/892676

Inventors:

Ralf Geiben Lynn - Watertown MA, US
Bruce D. Walker - Milton MA, US

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

The invention includes compositions comprising substantially purified serpin that are useful in methods for the treatment and prevention of HIV infection. The invention also includes methods for the treatment and prevention of HIV infection comprising contacting a composition of the invention with a human patient or treating HIV infection by introducing into a cell susceptible to HIV infection a DNA molecule encoding a serpin. Additionally, the invention includes antibodies and kits useful in the detection, treatment, and prevention of HIV infection.

US Patent:

8647822, Feb 11, 2014

Filed:

Nov 28, 2008

Appl. No.:

12/745220

Inventors:

Rafick-Pierre Sekaly - St.-Laurent, CA
Elias Haddad - Saint-Laurent, CA
Bruce Walker - Charlestown MA, US
Quentin Eichbaum - Charlestown MA, US

Assignee:

Oregon Health & Science University - Portland OR
Massachusetts General Hospital - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 611, 435 613

Abstract:

Modulation of PD-1 activity in the presence or absence of an agent as measured by a gene expression profile of at least two genes is provided. Reagents, kits, methods and uses thereof for the modulation of immune function comprise the identification of modulators of PD-1 activity.

US Patent:

20020127698, Sep 12, 2002

Filed:

Jan 25, 2002

Appl. No.:

10/057613

Inventors:

Ralf Geiben Lynn - Watertown MA, US
Bruce Walker - Milton MA, US

International Classification:

A61K039/21
A61K038/43
C12N007/01

US Classification:

435/235100, 424/094100, 424/208100

Abstract:

The invention includes compositions comprising substantially purified serpin that are useful in methods for the treatment and prevention of HIV infection. The invention also includes methods for the treatment and prevention of HIV infection comprising contacting a composition of the invention with a human patient or treating HIV infection by introducing into a cell susceptible to HIV infection a DNA molecule encoding a serpin. Additionally, the invention includes antibodies and kits useful in the detection, treatment, and prevention of HIV infection.

US Patent:

20020168353, Nov 14, 2002

Filed:

Jan 25, 2002

Appl. No.:

10/057593

Inventors:

Ralf Lynn - Watertown MA, US
Bruce Walker - Milton MA, US

International Classification:

A61K038/44

US Classification:

424/094400

Abstract:

The invention includes compositions comprising substantially purified peroxiredoxin that are useful in methods for the treatment and prevention of HIV-1 infection. The invention also includes methods for the treatment and prevention of HIV-1 infection comprising contacting a composition of the invention with a human patient. Additionally, the invention includes antibodies and kits useful in the treatment and prevention of HIV-1 infection.

US Patent:

20040001845, Jan 1, 2004

Filed:

May 20, 2003

Appl. No.:

10/442909

Inventors:

Marcus Altfeld - Arlington MA, US
Xu Yu - Cambridge MA, US
Bruce Walker - Milton MA, US
Marylyn Addo - Arlington MA, US

International Classification:

A61K039/21
A61K039/00

US Classification:

424/185100, 424/188100

Abstract:

The invention provides compositions containing HIV epitopes, which are recognized by cytotoxic T lymphocytes (CTL). Such polypeptides are used in vaccines and immunotherapies. HIV-1 epitopes represent early targets in a naturally-occurring response against HIV-1 infection.